close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Aandelen Lijst・Lyell Immunopharma Inc
Search

Lyell Immunopharma Inc

Gesloten

23.77 5.18

Neutraal

Prijsupdate 16 jan 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.6

Max

24.27

Belangrijke statistieken

By Trading Economics

Inkomsten

3.8M

-39M

Verkoop

7K

15K

EPS

-2.13

Winstmarge

-258,973.333

Werknemers

300

EBITDA

6.3M

-36M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+24.29% upside

Dividenden

By Dow Jones

Volgende Winsten

9 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

165M

505M

Vorige openingsprijs

18.59

Vorige sluitingsprijs

23.77

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

0.4217 / 0.4691 Steun & Weerstand

Lyell Immunopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

DJ

Lezen

17 jan 2026, 15:06 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

DJ

Lezen

17 jan 2026, 10:30 UTC

Winsten

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

DJ

Lezen

17 jan 2026, 03:10 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

DJ

Lezen

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

DJ

Lezen

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

DJ

Lezen

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

DJ

Lezen

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

DJ

Lezen

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

16 jan 2026, 21:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

DJ

Lezen

16 jan 2026, 21:41 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

DJ

Lezen

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

DJ

Lezen

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

DJ

Lezen

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

DJ

Lezen

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

DJ

Lezen

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

DJ

Lezen

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

DJ

Lezen

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

DJ

Lezen

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

DJ

Lezen

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

DJ

Lezen

16 jan 2026, 19:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

DJ

Lezen

16 jan 2026, 18:53 UTC

Marktinformatie

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

DJ

Lezen

16 jan 2026, 18:41 UTC

Marktinformatie

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

DJ

Lezen

16 jan 2026, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

DJ

Lezen

16 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

16 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

16 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

16 jan 2026, 17:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Lyell Immunopharma Inc Prognose

Koersdoel

By TipRanks

24.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.5 USD  24.29%

Hoogste 45 USD

Laagste 12 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lyell Immunopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

1

Buy

0

Hold

1

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Lyell Immunopharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.4217 / 0.4691Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Gemiddeld Termijn

Weak Bearish Evidence

There is one bearish event.

Lange Termijn

No Evidence

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

MDT

Medtronic PLC

96.83

↓-2.02%

A

Agilent Technologies Inc

139.62

↓-3.71%

VEEV

Veeva Systems Inc

222.3

↑ +1.47%

HQY

HealthEquity Inc

85.02

↓-2.1%

NEOG

Neogen Corp

9.24

↓-2.22%
help-icon Live chat